Genmab(GMAB) - 2024 Q2 - Quarterly Report

Exhibit 99.1 Genmab Announces Financial Results for the First Half of 2024 August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights "In the second quarter of 2024, we reached a number of significant milestones for the company. The acquisition of ProfoundBio, along with the regulatory approvals for EPKINLY and Tivdak, further solidify our commitment to the development of differentiated antibody therapies and will advance Genmab towards our ambitious 2030 visi ...